WO2000069259A1 - Solution aqueuse de conservation de tissus et d'organes - Google Patents
Solution aqueuse de conservation de tissus et d'organes Download PDFInfo
- Publication number
- WO2000069259A1 WO2000069259A1 PCT/FR2000/001336 FR0001336W WO0069259A1 WO 2000069259 A1 WO2000069259 A1 WO 2000069259A1 FR 0001336 W FR0001336 W FR 0001336W WO 0069259 A1 WO0069259 A1 WO 0069259A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- millimoles
- solution
- preservation
- solution according
- aqueous
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
- A01N1/0221—Freeze-process protecting agents, i.e. substances protecting cells from effects of the physical process, e.g. cryoprotectants, osmolarity regulators like oncotic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
- Y10T436/108331—Preservative, buffer, anticoagulant or diluent
Definitions
- tissues in particular but not limited to the veins, arteries, valves, vessels ....
- organ preservation solution is meant a single aqueous preservation solution capable of preserving a multitude of organs, and in particular, but not limited to, the liver, the heart and the kidney.
- the organ (s) or tissue (s) are subjected to an inevitable period of ischemia before being transplanted into a recipient. Consequently, the liquids used for the preservation of organs must simultaneously fulfill three objectives, namely: • washing the graft of residual blood,
- organ preservation is static hypothermic preservation. This method consists of rinsing the removed organ with a cooled preservation solution, then keeping the organ in this solution until the time of the subsequent transplant.
- this method ensures the preservation of the organs for only a limited period, this period hardly exceeding 24 hours for the kidney, 12 to 18 hours for the liver and 4 to 6 hours for the heart.
- Organ preservation liquids previously offered have different compositions depending on the organs to be preserved.
- the EURO COLLINS liquid marketed by FRESENIUS resulting from a mixture of the intracellular type (potassium concentration higher than the sodium concentration) exclusively ionic, that is to say free from any macromolecule and the BELZER-VTASPAN liquid also known as UW (University of Wisconsin) marketed by DUPONT.
- the BELZER-VTASPAN liquid also known as UW (University of Wisconsin) marketed by DUPONT.
- UW Universality of Wisconsin
- compositions of each of these liquids are shown in Table 1 below.
- the solution used for cardiac preservation is of the extracellular type (rich in sodium), while the preservation solution for the preservation of the kidney and liver is of the intracellular type ( rich in potassium).
- the problem which the invention proposes to solve is to provide a single solution capable of ensuring the conservation of any organ, and in particular of the liver, kidney and heart.
- Another object of the invention is to prepare a solution which is capable not only of preserving the organs, but also of preserving the tissues.
- Another objective of the invention is to increase the duration and the quality of the preservation.
- the invention provides an aqueous solution for preserving tissues and organs.
- This solution is characterized in that it is of the extracellular type and in that it comprises calcium ions (Ca 2+ ) and purified polyethylene glycol of molecular weight equal to 35,000.
- solution of the extracellular type is meant a solution comprising a sodium (Na + ) concentration of at least 30 millimoles, advantageously 125 millimoles.
- a cardioplegic solution is obtained.
- the extracellular solution of the invention made it possible to ensure not only the preservation of the heart and the tissues, but also the preservation of organs such as the kidney and the liver, for which solutions of the intracellular type have hitherto been proposed.
- the Applicant has found that the presence of calcium within the extracellular composition made it possible to conserve not only the heart, but also the other organs of the liver and kidney type, for which the calcium was previously absent.
- the PEG is a purified non-linear PEG, that is to say a PEG synthesized from PEG molecules of lower molecular weight.
- the purification is carried out by dialysis with the aim of removing all the molecules resulting from the oxidation of PEG or necessary for its manufacture, in particular molecules with a molecular weight of less than 15,000.
- the concentration of Ca 2+ ions is between 0.1 and 2 millimoles, advantageously 0.5 millimoles.
- the macromolecule has a molecular weight equal to 35,000, making it possible to guarantee the oncotic pressure, thereby improving the efficiency of preservation.
- said macromolecule improves the glomerular and tubular functions and produces a diuretic effect.
- the polyethylene glycol concentration of the solution of the invention is between 0.01 and 5 millimoles, preferably less than 1 millimole, advantageously equal to 0.03 millimoles.
- the aqueous preservation solution of the invention further comprises an impermeable anion, a sugar, a membrane stabilizing agent, a buffer solution, an anti-free radical agent and a source of energy.
- the pH of the solution of the invention is between 6.5 and 8, advantageously 7.4.
- the aqueous preservation solution further comprises: - from 20 to 40 millimoles of raffinose,
- the aqueous preservation solution of the invention comprises: Raffinose 30 millimoles PEG 35000 purified 0.03 millimoles MgS0 4 5 millimoles KH 2 PO 4 25 millimoles CaCl 2 0.5 millimoles Gluthation 3 millimoles Adenosine 5 millimoles Allopurinol 1 millimole
- the storage solution of the invention applies to static hypothermic storage and is used at a temperature between 2 and 10 ° C, advantageously 4 ° C.
- the preparation of the solution consists in dissolving all the constituents in an aqueous solution, the pH of the solution obtained being reduced to 7.4 by addition of NaOH.
- the performances of the aqueous preservation solution of the invention were compared on the kidney and the liver with regard to the BELZER-VIASPAN solution marketed by DUPONT.
- KREPS Henseleit-bicarbonate enriched in energy substrate and containing albumin. We distinguish in this example three different groups:
- Group A control group directly perfused with the artificial solution without prior preservation
- Group B organ stored for a period of 24 hours ischemia at a temperature of 4 ° C in a BELZER-VTASPAN preservation solution before re-perfusion with the artificial solution;
- Group C organ stored for a period of 24 hours of ischemia at a temperature of 4 ° C in the storage solution of the invention.
- Bile flow after transplant is an index of good liver function. Bile flow rates were calculated after a 24 hour hypothermic retention period.
- the bile flow is stable during the two hours of infusion. As the table shows, bile flow is minimal during the first 30 minutes of infusion, then increases until it reaches a maximum after 60 minutes to remain stable during the second hour of infusion.
- liver preserved in the solution of the invention (C) has the highest bile flow (0.56).
- Indocyanine green by rapidly attaching to plasma proteins, is distributed in the vascular volume. It is specifically purified by the liver and concentrated in the bile. The presence of indocyanine green in the liver depends on the infusion rate and its excretion depends on the energy status of the hepatocytes. It follows that this parameter gives not only information on the integrity of endothelial cells, but also information on the integrity of hepatocytes
- Transaminases are intracellular enzymes. Their presence in the perfusate indicates cell lysis. The results are shown in the table below (Table 5).
- livers perfused with solution B of the intracellular type release more ASAT and ALAT than the livers stored in the solution of the invention of extracellular type (C).
- the replacement of hydroxyethyl starch in solution B with polyethylene glycol results in a significant decrease in cell lysis.
- Creatine kinase is an isoenzyme that is found specifically in endothelial cells. Its release in the perfusion liquid therefore shows lysis of these cells.
- endothelial cells undergo severe damage. The loss of viability of endothelial cells takes place only after infusion and the rate of cell death depends on the quality of storage and therefore on the storage solution.
- Time 0 referenced in the table below (Table 6) corresponds to the re-perfusion of the grafts. Under these conditions, the liquid recovered is the preservation liquid kept 24 hours in the liver.
- the measured CK-BB activity is therefore a marker for the damage to the endothelial cells suffered during the conservation period.
- solution C The effectiveness of the preservative liquid of the invention was compared with that of the BELZER-VIASPAN liquid (solution B) and EURO COLLINS (solution D).
- the urine flow rate of the kidneys perfused with liquid A remains lower than the urine flow rate of the kidneys without prior conservation.
- kidneys preserved in the solution of the invention have the highest flow rate.
- This parameter measures the glomerular function of the kidney and provides information on the glomerular filtration rate.
- solution C of the invention has a significant improvement.
- the sodium reabsorption rate measures renal tubular function. The results are shown in Table 9 below.
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2371057A CA2371057C (fr) | 1999-05-18 | 2000-05-18 | Solution aqueuse de conservation de tissus et d'organes |
AT00927362T ATE233483T1 (de) | 1999-05-18 | 2000-05-18 | Wässrige lösung zum konservieren von gewebe und organen |
BRPI0010314-4A BR0010314B1 (pt) | 1999-05-18 | 2000-05-18 | solução aquosa de conservação de tecidos e órgãos. |
DK00927362T DK1178726T3 (da) | 1999-05-18 | 2000-05-18 | Vandig opløsning til konservering af væv og organer |
AU45771/00A AU762062B2 (en) | 1999-05-18 | 2000-05-18 | Aqueous solution for preserving tissues and organs |
EP00927362A EP1178726B1 (fr) | 1999-05-18 | 2000-05-18 | Solution aqueuse de conservation de tissus et d'organes |
DE60001555T DE60001555T2 (de) | 1999-05-18 | 2000-05-18 | Wässrige lösung zum konservieren von gewebe und organen |
US09/988,936 US6641992B2 (en) | 1999-05-18 | 2001-11-19 | Aqueous solution for preserving tissues and organs |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR99/06434 | 1999-05-18 | ||
FR9906434A FR2793651B1 (fr) | 1999-05-18 | 1999-05-18 | Solution aqueuse de conservation de tissus et d'organes |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/988,936 Continuation US6641992B2 (en) | 1999-05-18 | 2001-11-19 | Aqueous solution for preserving tissues and organs |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000069259A1 true WO2000069259A1 (fr) | 2000-11-23 |
Family
ID=9545824
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2000/001336 WO2000069259A1 (fr) | 1999-05-18 | 2000-05-18 | Solution aqueuse de conservation de tissus et d'organes |
Country Status (11)
Country | Link |
---|---|
US (1) | US6641992B2 (fr) |
EP (1) | EP1178726B1 (fr) |
AT (1) | ATE233483T1 (fr) |
AU (1) | AU762062B2 (fr) |
BR (1) | BR0010314B1 (fr) |
CA (1) | CA2371057C (fr) |
DE (1) | DE60001555T2 (fr) |
DK (1) | DK1178726T3 (fr) |
ES (1) | ES2188542T3 (fr) |
FR (1) | FR2793651B1 (fr) |
WO (1) | WO2000069259A1 (fr) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10020507A1 (de) * | 2000-04-26 | 2001-11-08 | Wolfgang Thasler | Lösung zur Konservierung menschlicher Leberzellen, konservierte menschliche Leberzelle, ihre Herstellung und Verwendung |
EP1997374B1 (fr) * | 2007-05-31 | 2016-11-02 | Maco Pharma | Procédé de rinçage et de conservation d'un organe en vue de sa transplantation et solution mise en oeuvre dans ce procédé |
WO2021058892A1 (fr) | 2019-09-27 | 2021-04-01 | Institut Georges Lopez | Solution de préservation et/ou de rinçage d'organe á transplanter |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005041656A2 (fr) * | 2003-10-22 | 2005-05-12 | Fred Hutchinson Cancer Research Center | Procedes, compositions et dispositifs pour induire une stase dans des tissus et des organes |
US20050136125A1 (en) * | 2003-10-22 | 2005-06-23 | Roth Mark B. | Methods, compositions and devices for inducing stasis in cells, tissues, organs, and organisms |
US20050170019A1 (en) * | 2003-10-22 | 2005-08-04 | Fred Hutchinson Cancer Research Center | Methods, compositions and devices for inducing stasis in cells |
EP1809101B1 (fr) * | 2004-11-12 | 2016-11-02 | Organoflush B.V. | Composition pour la préservation et la perfusion à froid d'organes |
JP2008538569A (ja) * | 2005-04-20 | 2008-10-30 | フレッド ハッチンソン キャンサー リサーチ センター | 細胞、組織、臓器、および生物の生存能力を高めるための方法、組成物、および製造物 |
GB0712833D0 (en) | 2007-07-03 | 2007-08-08 | Aqix Ltd | Body Fluid Expander |
WO2010075509A1 (fr) * | 2008-12-26 | 2010-07-01 | Baylor Research Institute | Appareil et procédé de conservation des tissus pancréatiques et des cellules d'îlots pancréatiques, en vue d'une greffe |
FR2974708B1 (fr) * | 2011-05-02 | 2013-07-05 | Groupe Igl | Solution de rincage de greffon ou de tissu et procede de rincage dudit greffon ou tissu avant revascularisation |
CN102948412A (zh) * | 2011-08-26 | 2013-03-06 | Igl集团 | 用于保存组织和器官的水溶液 |
WO2013143822A1 (fr) | 2012-03-26 | 2013-10-03 | Imax Discovery Gmbh | Adénosine utilisée en tant que renforçateur de goût sucré pour certains sucres |
US10874098B2 (en) | 2015-04-03 | 2020-12-29 | Tx Innovations B.V. | Organ preservation composition |
PL3685665T3 (pl) * | 2019-01-23 | 2023-10-16 | Carnamedica Sp. Z O.O. | Zastosowanie roztworu zawierającego peg do przechowywania komórek macierzystych |
WO2021041836A1 (fr) * | 2019-08-28 | 2021-03-04 | The Regents Of The University Of Michigan | Conservation d'organes pour une transplantation et des interventions chirurgicales autre qu'une transplantation |
CN114271262B (zh) * | 2021-12-09 | 2023-05-12 | 四川大学华西医院 | 一种多器官保存液及其用途 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990013307A1 (fr) * | 1989-04-28 | 1990-11-15 | Waters Instruments, Inc. | Solution et procede de conservation d'organes |
WO1995002326A1 (fr) * | 1993-07-16 | 1995-01-26 | Cryomedical Sciences, Inc. | Solutions de preservation de tissus et de substitution sanguine et procedes utilisant lesdites solutions |
FR2723818A1 (fr) * | 1994-08-25 | 1996-03-01 | Implants & Instr Chirurg | Composition de perfusion pour ameliorer la conservation d'organes vivants |
WO1997022244A1 (fr) * | 1995-12-15 | 1997-06-26 | Stiftelsen Facthor | Solution de conservation |
WO1998035551A1 (fr) * | 1997-02-13 | 1998-08-20 | Lxr Biotechnology Inc. | Solution de preservation d'organes |
WO1999008514A1 (fr) * | 1997-08-20 | 1999-02-25 | Lxr Biotechnology, Inc. | Compositions contenant du polyethylene glycol et leurs utilisations |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4798824A (en) * | 1985-10-03 | 1989-01-17 | Wisconsin Alumni Research Foundation | Perfusate for the preservation of organs |
US5002965A (en) * | 1989-05-09 | 1991-03-26 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Use of ginkgolides to prevent reperfusion injury in organ transplantation |
US5145771A (en) * | 1990-04-12 | 1992-09-08 | The University Of North Carolina At Chapel Hill | Rinse solution for organs and tissues |
US5696152A (en) * | 1996-05-07 | 1997-12-09 | Wisconsin Alumni Research Foundation | Taxol composition for use as organ preservation and cardioplegic agents |
-
1999
- 1999-05-18 FR FR9906434A patent/FR2793651B1/fr not_active Expired - Fee Related
-
2000
- 2000-05-18 DK DK00927362T patent/DK1178726T3/da active
- 2000-05-18 DE DE60001555T patent/DE60001555T2/de not_active Expired - Lifetime
- 2000-05-18 ES ES00927362T patent/ES2188542T3/es not_active Expired - Lifetime
- 2000-05-18 EP EP00927362A patent/EP1178726B1/fr not_active Expired - Lifetime
- 2000-05-18 AT AT00927362T patent/ATE233483T1/de active
- 2000-05-18 BR BRPI0010314-4A patent/BR0010314B1/pt not_active IP Right Cessation
- 2000-05-18 CA CA2371057A patent/CA2371057C/fr not_active Expired - Lifetime
- 2000-05-18 AU AU45771/00A patent/AU762062B2/en not_active Ceased
- 2000-05-18 WO PCT/FR2000/001336 patent/WO2000069259A1/fr active IP Right Grant
-
2001
- 2001-11-19 US US09/988,936 patent/US6641992B2/en not_active Expired - Lifetime
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990013307A1 (fr) * | 1989-04-28 | 1990-11-15 | Waters Instruments, Inc. | Solution et procede de conservation d'organes |
WO1995002326A1 (fr) * | 1993-07-16 | 1995-01-26 | Cryomedical Sciences, Inc. | Solutions de preservation de tissus et de substitution sanguine et procedes utilisant lesdites solutions |
FR2723818A1 (fr) * | 1994-08-25 | 1996-03-01 | Implants & Instr Chirurg | Composition de perfusion pour ameliorer la conservation d'organes vivants |
WO1997022244A1 (fr) * | 1995-12-15 | 1997-06-26 | Stiftelsen Facthor | Solution de conservation |
WO1998035551A1 (fr) * | 1997-02-13 | 1998-08-20 | Lxr Biotechnology Inc. | Solution de preservation d'organes |
WO1999008514A1 (fr) * | 1997-08-20 | 1999-02-25 | Lxr Biotechnology, Inc. | Compositions contenant du polyethylene glycol et leurs utilisations |
Non-Patent Citations (3)
Title |
---|
CRYOBIOLOGY, vol. 27, no. 1, 1990, pages 1 - 8 * |
DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; D.C.MARSH ET AL.: "Hypothermic preservation of hepatocytes. II. Importance of calcium and amino acids", XP002130968, retrieved from STN-INTERNATIONAL accession no. 112:136600 * |
W.N.NICOMB ET AL.: "OPTIMAL CARDIOPLEGIA AND 24-HOUR HEART STORAGE WITH SIMPLIFIED UW SOLUTION CONTAINING POLYETHYLENE GLYCOL", TRANSPLANTATION, vol. 49, no. 2, February 1990 (1990-02-01), pages 261 - 263, XP002130967 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10020507A1 (de) * | 2000-04-26 | 2001-11-08 | Wolfgang Thasler | Lösung zur Konservierung menschlicher Leberzellen, konservierte menschliche Leberzelle, ihre Herstellung und Verwendung |
EP1997374B1 (fr) * | 2007-05-31 | 2016-11-02 | Maco Pharma | Procédé de rinçage et de conservation d'un organe en vue de sa transplantation et solution mise en oeuvre dans ce procédé |
WO2021058892A1 (fr) | 2019-09-27 | 2021-04-01 | Institut Georges Lopez | Solution de préservation et/ou de rinçage d'organe á transplanter |
FR3101227A1 (fr) | 2019-09-27 | 2021-04-02 | Institut Georges Lopez | Solution de préservation et/ou de rincage d’organe a transplanter |
Also Published As
Publication number | Publication date |
---|---|
BR0010314A (pt) | 2002-02-13 |
EP1178726A1 (fr) | 2002-02-13 |
DE60001555T2 (de) | 2003-10-02 |
AU4577100A (en) | 2000-12-05 |
AU762062B2 (en) | 2003-06-19 |
ES2188542T3 (es) | 2003-07-01 |
FR2793651A1 (fr) | 2000-11-24 |
FR2793651B1 (fr) | 2003-05-16 |
ATE233483T1 (de) | 2003-03-15 |
DE60001555D1 (de) | 2003-04-10 |
CA2371057A1 (fr) | 2000-11-23 |
US20020068265A1 (en) | 2002-06-06 |
DK1178726T3 (da) | 2003-06-10 |
US6641992B2 (en) | 2003-11-04 |
CA2371057C (fr) | 2010-10-05 |
EP1178726B1 (fr) | 2003-03-05 |
BR0010314B1 (pt) | 2011-05-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1178726B1 (fr) | Solution aqueuse de conservation de tissus et d'organes | |
US5145771A (en) | Rinse solution for organs and tissues | |
Pellerin-Mendes et al. | In vitrostudy of the protective effect of trehalose and dextran during freezing of human red blood cells in liquid nitrogen | |
FR2625073A1 (fr) | Liquide de perfusion pour la conservation d'organes | |
US6140123A (en) | Method for conditioning and cryopreserving cells | |
CA2522941A1 (fr) | Methodes et solutions ameliorees de stockage des organes de donneurs | |
EP1057405A1 (fr) | Agent de stockage pour la préservation des cellules, des tissus ou des organes d'animaux, et procédé correspondant | |
WO2000027189A1 (fr) | Solution de perfusion et/ou de conservation et/ou de reperfusion lors de la transplantation d'organes | |
JP2010180257A (ja) | ドナー器官のためのフラッシュ保存溶液 | |
FR2956289A1 (fr) | Formulation liquide avec gaz dissous utilisable pour conserver de la matiere biologique | |
CN102948412A (zh) | 用于保存组织和器官的水溶液 | |
Mamprin et al. | Glutathione content during the rinsing and rewarming process of rat hepatocytes preserved in University of Wisconsin solution | |
WO2021058892A1 (fr) | Solution de préservation et/ou de rinçage d'organe á transplanter | |
Třeška et al. | Can ischemia-reperfusion syndrome in transplanted kidneys procured from non–heart-beating donors be influenced by adding selenium into the reperfusion solution? an experimental study | |
Leonhardt et al. | The effect of different solutions for organ preservation on immediate postischemic pancreatic function in vitro | |
EP2704559B1 (fr) | Solution de rincage de greffon ou de tissu et procede de rincage dudit greffon ou tissu avant revascularisation | |
FR2723818A1 (fr) | Composition de perfusion pour ameliorer la conservation d'organes vivants | |
FR2600671A1 (fr) | Procede de conservation cryogenique de substances et matieres organiques, notamment de cellules | |
Azelvandre et al. | Rheological behaviour of stored blood cells | |
Basso et al. | Renal preservation with hyperbaric oxygenation and hypothermia | |
KR100304594B1 (ko) | 이식용 장기 및 혈액세포 보존제의 조성물 | |
EP1997374B1 (fr) | Procédé de rinçage et de conservation d'un organe en vue de sa transplantation et solution mise en oeuvre dans ce procédé | |
FR2923391A1 (fr) | Compositions pour conserver des cellules, des tissus ou des organes, procede d'obtention et utilisations. | |
Klempnauer et al. | Hypothermic preservation of the rat pancreas | |
JPH09328401A (ja) | 臓器保存液 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2000927362 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2371057 Country of ref document: CA Ref country code: CA Ref document number: 2371057 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 45771/00 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09988936 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2000927362 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 2000927362 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 45771/00 Country of ref document: AU |
|
NENP | Non-entry into the national phase |
Ref country code: JP |